The University of Iowa has independently funded and established mentors in Surgical Oncology to train the next generation of surgeon-scientists to independently conduct basic, translational and clinical research. Trainees will be MD or MO PhD post-graduates who have completed at least two years of surgical residency training. Three training slots per year are sought in a typical two year training program in either a Basic Science or Clinical Research Track. Program leadership is provided by the Head of the Department of Surgery, who serves as Chair of the eight member Executive Committee. Three Associate Directors for Basic Science Research help administer the Basic Science Research Track. Three Associate Directors for Clinical Research help administer the Clinical Research Track. The Executive Committee will monitor progress through periodic oral and written reports from both the Trainee and the individual Trainee's three or four member Trainee Advisory Committee. Preceptors actively collaborate through the University of Iowa's NCI-designated Holden Comprehensive Cancer Center and the NIH-designed Institute for Clinical and Translational Science. Additional guidance will be provided by a six member External Advisory Committee, comprised of national leaders in Surgical Oncology with experience in administrating T32 training programs. Two Diversity Advisers (one internal, one external) will assist in recruitment and retention of underrepresented Trainees. Research training will consist of: (1) required core curriculum including training in research design, management, ethics and data analysis, (2) an individualized curriculum developed in collaboration with the Preceptor and Trainee Advisory Committee, (3) Preceptor-directed research project in either a basic science laboratory or clinical research group, (4) basic and clinical science-oriented interactive seminars, and (5) attendance at national meetings. Trainees will be provided with the fundamental skill sets, knowledge and experience needed to successfully compete for independent research funding in Surgical Oncology.
The need for surgical oncologists trained in research disciplines is critical. Surgeons are often the first health care professionals to treat cancer patients. A thorough understanding of cancer biology is essential in enabling the surgeon to advance the treatment of patients with solid organ malignancies and to be a successful clinician in a multidisciplinary team.
|Bogachek, Maria V; Park, Jung M; De Andrade, James P et al. (2016) Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem Cell Reports 7:1140-1151|
|Maxwell, Jessica E; Sherman, Scott K; O'Dorisio, Thomas M et al. (2016) Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery 159:320-33|
|Maxwell, Jessica E; O'Dorisio, Thomas M; Howe, James R (2016) Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 25:171-94|
|Doskey, Claire M; Buranasudja, Visarut; Wagner, Brett A et al. (2016) Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy. Redox Biol 10:274-284|
|Maxwell, Jessica E; Sherman, Scott K; Howe, James R (2016) Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 22:5022-5029|
|De Andrade, James P; Park, Jung M; Gu, Vivian W et al. (2016) EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. Mol Cancer Ther 15:503-11|
|Park, J M; Wu, T; Cyr, A R et al. (2015) The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis. Oncogene 34:6105-14|
|Hrabe, Jennifer E; O'Leary, Brianne R; Fath, Melissa A et al. (2015) Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor Î²-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells. Redox Biol 5:319-27|
|Sherman, Scott K; Maxwell, Jessica E; Qian, Qining et al. (2015) Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations. Cancer Genet 208:41-6|
|Du, Juan; Cieslak 3rd, John A; Welsh, Jessemae L et al. (2015) Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Cancer Res 75:3314-26|
Showing the most recent 10 out of 51 publications